Chronic myeloid leukemia, or CML, is a rare form of leukemia that causes too many white blood cells to be formed and build up in the blood and bone marrow. It accounts for about 15% of leukemias in adults. The BCR::ABL gene fusion is the oncogenic driver for patients with chronic myeloid leukemia. BCR::ABL1 tyrosine kinase inhibitors (TKIs) are the mainstay of treatment for chronic myeloid leukemia. Several TKIs have been approved over the years, including Novartis' Gleevec/Glivec, Bristol Myers Squibb's Sprycel, Novartis' Tasigna, and Pfizer's Bosulif.
The company we are profiling today is Enliven Therapeutics Inc. (ELVN), which is developing a drug for CML with the goal of delivering differentiated efficacy, improved tolerability, and greater convenience than the approved TKIs, and with the potential to compete across all lines of CML treatment.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.